Abstract:Background: L-type CaV1.2 channels play crucial roles in the regulation of blood pressure. Galectin-1 (Gal-1) has been reported to bind to the I-II loop of CaV1.2 channels to reduce their current density. However, the mechanistic understanding for the downregulation of CaV1.2 channels by Gal-1 and whether Gal-1 plays a direct role in blood pressure regulation remain unclear. Methods: In vitro experiments involving coimmunoprecipitation, Western blot, patch-clamp recordings, immunohistochemistry, and pressure myography were used to evaluate the molecular mechanisms by which Gal-1 downregulates CaV1.2 channel in transfected, human embryonic kidney 293 cells, smooth muscle cells, arteries from Lgasl1−/− mice, rat, and human patients. In vivo experiments involving the delivery of Tat-e9c peptide and AAV5-Gal-1 into rats were performed to investigate the effect of targeting CaV1.2-Gal-1 interaction on blood pressure monitored by tail-cuff or telemetry methods. Results: Our study reveals that Gal-1 is a key regulator for proteasomal degradation of CaV1.2 channels. Gal-1 competed allosterically with the CaV&bgr; subunit for binding to the I-II loop of the CaV1.2 channel. This competitive disruption of CaV&bgr; binding led to CaV1.2 degradation by exposing the channels to polyubiquitination. It is notable that we demonstrated that the inverse relationship of reduced Gal-1 and increased CaV1.2 protein levels in arteries was associated with hypertension in hypertensive rats and patients, and Gal-1 deficiency induces higher blood pressure in mice because of the upregulated CaV1.2 protein level in arteries. To directly regulate blood pressure by targeting the CaV1.2-Gal-1 interaction, we administered Tat-e9c, a peptide that competed for binding of Gal-1 by a miniosmotic pump, and this specific disruption of CaV1.2-Gal-1 coupling increased smooth muscle CaV1.2 currents, induced larger arterial contraction, and caused hypertension in rats. In contrasting experiments, overexpression of Gal-1 in smooth muscle by a single bolus of AAV5-Gal-1 significantly reduced blood pressure in spontaneously hypertensive rats. Conclusions: We have defined molecularly that Gal-1 promotes CaV1.2 degradation by replacing CaV&bgr; and thereby exposing specific lysines for polyubiquitination and by masking I-II loop endoplasmic reticulum export signals. This mechanistic understanding provided the basis for targeting CaV1.2-Gal-1 interaction to demonstrate clearly the modulatory role that Gal-1 plays in regulating blood pressure, and offering a potential approach for therapeutic management of hypertension.

Regulation of Blood Pressure by Targeting CaV1.2-Galectin-1 Protein Interaction.

Splice Variant Specific Modulation of Ca V 1.2 Calcium Channel by Galectin-1 Regulates Arterial Constriction

Chronic Reduction in Paraventricular Nucleus (PVN) AT1R Expression by AAV‐mediated Transfer of a Small Hairpin RNA (shrna) Produces a Decrease in Blood Pressure in Spontaneously Hypertensive Rats

Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension

YAP-galectin-3 Signaling Mediates Endothelial Dysfunction in Angiotensin II-induced Hypertension in Mice.

Gstp1 Negatively Regulates Blood Pressure in Hypertensive Rat Via Promoting APLNR Ubiquitination Degradation Mediated by Nedd4

NGAL is a Novel Target in Hypertension by Modulating the NCC-Mediated Renal Na Balance

α1C S1928 Phosphorylation of CaV1.2 Channel Controls Vascular Reactivity and Blood Pressure

Gallic Acid Attenuates Angiotensin II-Induced Hypertension and Vascular Dysfunction by Inhibiting the Degradation of Endothelial Nitric Oxide Synthase

Alleviating Hypertension by Selectively Targeting Angiotensin Receptor-Expressing Vagal Sensory Neurons

Novel Smooth Muscle Ca2+-Signaling Nanodomains in Blood Pressure Regulation

Dominant role of CACNA1D exon mutations for blood pressure regulation

S-Nitrosylation-Mediated Reduction of CaV1.2 Surface Expression and Open Probability Underlies Attenuated Vasoconstriction Induced by Nitric Oxide

Effects of regulator of G protein signaling 2 (RGS2) overexpression in the paraventricular nucleus on blood pressure in rats with angiotensin II-induced hypertension

Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm

Gallic Acid Attenuates Hypertension, Cardiac Remodeling, and Fibrosis in Mice with N G-nitro-L-arginine Methyl Ester-Induced Hypertension Via Regulation of Histone Deacetylase 1 or Histone Deacetylase 2

S-Nitrosylation-Mediated Reduction of Ca<sub>V</sub>1.2 Surface Expression and Open Probability Underlies Attenuated Vasoconstriction Induced by Nitric Oxide

Vascular smooth muscle cells specific deletion of angiopoietin-like protein 8 prevents angiotensin II-promoted hypertension and cardiovascular hypertrophy

Increased CaMKII activation and contrast changes of cardiac β1-and β3-Adrenergic signaling pathways in a humanized angiotensinogen model of hypertension

Angiotensin II-induced Hypertension is Reduced by Deficiency of P-selectin Glycoprotein Ligand-1

Role of Gi proteins in the regulation of blood pressure and vascular remodeling